25 May 2013
Keywords: anormed, mozobil, sees, good, ph, ii, results
Article | 12 September 2005
Vancouver, Canada-based drugmaker AnorMED says that a study published in the current issue of the journal Blood demonstrates that cancer
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com